Effectiveness and Safety of Dysport® (abobotulinumtoxinA) in Paediatric Lower Limb Spasticity

Inclusion Criteria:

- Female or male subjects aged 2 to 17 years inclusive

- Decision to prescribe abobotulinumtoxinA, to be made prior to and independently from
the decision to enroll in the study

- Primary diagnosis of paediatric lower limb (PLL) spasticity and either: Previously
untreated with BoNT (naïve to BoNT), or previously treated with a BoNT (i.e. non naïve
to BoNT), and for those who were previously treated with BoNT-A, they should have
responded to BoNT-A treatment according to the investigator's criteria

- For non naïve BoNT subjects, a minimum interval of 12 weeks since the last BoNT
injection and in the presence of spasticity

Exclusion Criteria:

- Known resistance to any BoNT or experienced serious safety issues with previous use of
BoNT

- Concomitant treatment with other BoNT

- Known hypersensitivity to abobotulinumtoxinA or related compounds, or any component in
the study drug formulation

- Subjects with any clinical (or subclinical) evidence of marked defective neuromuscular
transmission (e.g. Lambert Eaton syndrome or myasthenia gravis) or persistent
clinically significant neuromuscular disorders